Tajikistan, a Frail Nation-State Amidst the New “Great Game”
Nuvilex - Phase 2 data for Pancreatic Cancer treatment ($NVLX)
Pfizer (NYSE:PFE) Pays Record 1.3 Billion Penalty for Drug Misbranding
Another drug stock that I really like is Endo Pharmaceuticals (ENDP). Endo Pharmaceuticals is a midcap biotechnology company that is know for developing and selling pain management drugs and therapies. This company may be a good investment as a play on an aging baby boomer population. The generic pharmaceutical market is a highly profitable market as drug patents expire from bigger name players.
GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
GenVec, Inc. reported today that the U.S. Food and Drug Administration (FDA) has approved GenVec’s TNFerade™ for Fast Track development in the treatment of locally advanced pancreatic cancer. TNFerade™ is designed to stimulate the production of immune system proteins with anti-cancer properties that are injected into tumors.
Drugstore.com, Inc. (DSCM) Announces Third Quarter Financial Results; Expects Profitability in the Fourth Quarter
Drugstore.com, Inc. (NASD: DSCM), a leading online provider of health, beauty, vision, and pharmacy products, recently reported its financial results for the third quarter ended September 28, 2008. The company reported an 8.5 percent year-over-year increase in quarterly sales to $87.8 million and a net loss of $3.6 million, or a loss of $0.04 per share.
China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board
China Pharma Holdings Inc. (OTCBB: CPHI) develops, manufactures and markets generic and branded specialty pharmaceutical products in China. The company today announced its third-quarter results for the period ended September 30, 2008, marking significant increases in revenues and net income.
BioScrip (BIOS) Quarterly Revenue and Net Income Soars
BioScrip, Inc., the specialty pharmacy and pharmacy services provider, had a double dose of good news today with the announcement of exceptional second quarter revenue and earnings figures. Consolidated revenue grew to $348.4 million, an 18.2% increase over the same period last year. Specialty Services revenue shot up to $298.2 million, a 25.3% over the prior year.
Lpath Inc. (LPTN.OB) Secures Strategic $23M Alliance to Launch Cancer Treatment Trials
Oftentimes money can stand in the way of health. In light of our current economic woes, many individuals find that the rising cost of healthcare outweighs the need for insurance and proper care. The same goes for scientific and medical companies in need of funding for further research and development.